Peter Coelho, MD
Family Medicine · Hollister, CANPI 1285740480
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 38.8% of the total. Reporting peaked in 2022 at $2,895 and has fallen 89.1% since, to $316 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $41.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Terumo Medical Corporation$2K
- GSK$627
- AstraZeneca$253
- Novo Nordisk$210
- Johnson & Johnson$196
- plus $847 from 18 others
Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
What the payments were for
- Consulting fees$2,10030%
- Speaking & faculty fees$2,25032%
- Food & beverage$2,54937%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $2,689 |
| Terumo Medical Corporation | 1 | $2,100 |
| GSK | 44 | $627 |
| AstraZeneca | 5 | $253 |
| Novo Nordisk | 26 | $210 |
| Johnson & Johnson(2 entities) | 21 | $196 |
| Abbott | 14 | $195 |
| Coala Life Inc | 3 | $134 |
| Bayer | 2 | $120 |
| Amgen(2 entities) | 4 | $61 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Exact Sciences | 2 | $35 |
| Pfizer | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Optinose US, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| Novartis | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,923 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $174,008 |
| JardianceEmpagliflozin | 93 | $142,993 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $53,830 |
| FarxigaDapagliflozin Propanediol | 36 | $53,285 |
| XareltoRivaroxaban | 28 | $42,178 |
| MounjaroTirzepatide | 17 | $33,609 |
| ProliaDenosumab | 16 | $27,877 |
| TrulicityDulaglutide | 15 | $26,919 |
| EliquisApixaban | 21 | $20,767 |
| JanuviaSitagliptin Phosphate | 11 | $17,562 |
| MyrbetriqMirabegron | 15 | $11,856 |
| Spiriva RespimatTiotropium Bromide | 12 | $11,545 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,630 |
| Testosterone | 40 | $6,930 |
| Rosuvastatin Calcium | 323 | $5,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $210 | $174,008107 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $27 | $154,538105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $29 | $60,52932 claims |
| GSKTrelegy Ellipta | $627 | $53,83067 claims |
| AstraZenecaFarxiga | $253 | $53,28536 claims |
| Johnson & JohnsonXarelto | $196 | $42,17828 claims |
| AmgenProlia | $61 | $27,87716 claims |
| PfizerEliquis, Paxlovid | $32 | $23,62541 claims |
| MerckJanuvia | $11 | $17,56211 claims |
| AbbVieSynthroid, Armour Thyroid | $2,689 | $2,81459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Hollister
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.